Special Issue

Precision Medicine in Clinical Practice

Message from the Guest Editors

Precision medicine is a dynamic area embracing diverse approaches that allow the targeting of new medicines, screening programs or preventive healthcare strategies, including the use of genomic technologies, also potentially taking account of patient preferences. Health insurance plans are increasingly considering different precision medicine interventions for coverage and reimbursement. Precision medicine interventions are also being integrated into clinical care for a range of medical conditions and purposes. The *Journal of Personalized Medicine* aims to publish a collection of articles that explore challenges and opportunities in the field and fresh insights to ongoing discussions and debate in precision medicine from the US and abroad. We will consider original research, systematic reviews, and well-designed case studies and analyses that report empirical work presenting experiences and perspectives about integrating precision medicine in clinical practice.

### Guest Editors

Dr. Christine Lu
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA

Prof. Adam Buchanan
Associate Professor and Director of Geisinger Genomic Medicine Institute, Danville, PA, USA

Deadline for manuscript submissions

closed (10 December 2022)

Journal of Personalized Medicine

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).